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A B S T R A C T   
Introduction: Chinese herbal medicine (CHM) and probiotics are two complementary and alternative approaches 
often used for irritable bowel syndrome (IBS). This study evaluates the efficacy and safety of CHM compared 
with probiotics for IBS. 
Methods: 11 databases were searched (up until March 2020) for randomized controlled trials of IBS. Risk of bias 
was evaluated. RevMan 5.3 was used for data synthesis. Trial sequential analysis (TSA) was used to control for 
risk of random errors. 
Results: A total of 47 trials were includedin the analysis. Unclear risk of bias was observed for most domains of 
included trials. CHM had advantages over probiotics for improving overall symptoms of IBS-Diarrhea (IBS-D) 
(RR 1.24, 95 % CI 1.18–1.30, 3207 patients, I2 = 55 %, very low certainty). The heterogeneity might be as-
sociated with different diagnostic criteria, duration of treatment, probiotic composition and types of CHM. CHM 
might provide better outcomes than probiotics when the duration of treatment is more than 4 weeks (RR 1.26, 
95 % CI 1.20–1.33, 2669 patients, very low), and the formulae represented by Tongxie Yaofang appeared to be 
better than triple Bifidobacterium preparations for improving overall symptoms of IBS-D (RR 1.33, 95 % CI 
1.20–1.47, 476 patients). CHM might reduce relapse rate compared with probiotics (RR 0.27, 95 % CI 
0.18−0.40, 382 patients, very low). Adverse events were mainly gastrointestinal symptoms. 
Conclusions: Very low quality evidence suggests that CHM may be better than probiotics for improving overall 
symptoms of IBS-D when the duration of treatment lasted more than 4 weeks ; and CHM may be better than 
probiotics for reducing relapse rates of IBS-D.   
1. Introduction 
Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) 
that manifests as recurrent episodes of abdominal pain associated with 
altered bowel habits, accompanied by symptoms of abdominal bloating 
or distension. Symptoms occur for at least 6 months before diagnosis 
and during the last 3 months. According to an individual’s abnormal 
bowel habits, IBS is divided into three main subtypes: IBS with pre-
dominant constipation (IBS-C), IBS with predominant diarrhea (IBS-D), 
and IBS with mixed bowel habits (IBS-M). Different subtypes can be 
transformed into each other over time [1]. 
The prevalence of IBS varies according to different diagnostic cri-
teria. A general population survey using Rome IV criteria in the United 
States, United Kingdom and Canada showed that the prevalence of IBS 
was 5.7 % [2]. IBS can significantly reduce work efficiency and quality 
of life [3–6]. Conventional medications for IBS target the main bowel 
symptoms by using antidiarrheals, 5-HT3 receptor antagonists, and 
antispasmodics for IBS-D; fiber supplements, laxative agents, and pro-
secretory agents for IBS-C; other symptomatic medications (such as 
antidepressants, antibiotics) [7]. 
As conventional medications are often symptomatic and have lim-
ited efficacy [8,9], Complementary and Alternative Medicine (CAM) is 
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increasingly favored by IBS patients. An Australian study showed that 
about 20 % IBS patients had sought alternative health care approaches 
for gastrointestinal problems [10]. A UK study found that about 51 % of 
IBS outpatients had used CAM [11]. A prospective study in the United 
States showed that 35 % of patients with functional bowel diseases, 
including IBS, claimed to have used at least one type of CAM during a 6- 
month follow-up [12]. Probiotics and Chinese herbal medicines (CHM) 
are two commonly used CAM therapies for IBS [8,13–15]. Although 
actual clinical practice is always not consistent with evidence-based 
expert recommendations for the use of probiotics, one study showed 
that among surveyed doctors most recommended probiotics for IBS 
patients and believed that probiotics were safe for most patients with 
gastric problems [16]. Probiotics are living microorganisms that can 
bring health benefits to the host when administered in sufficient 
quantities. Synbiotics are a mixture of probiotics and prebiotics that 
have a synergistic effect on the growth and survival of beneficial or-
ganisms [17]. Meta-analysis showed that probiotics might play a ben-
eficial role in improving some IBS symptoms [18,19]. The efficacy of 
CHM in the treatment of IBS has always received much attention. Since 
the first systematic review (SR) of herbal medicine for IBS published on 
Cochrane collaboration network in 2006 [20], a large number of ran-
domized controlled trials (RCTs) [21–23] and SRs [24–27] of CHM for 
IBS have been published in recent years. CHM are generally considered 
effective for IBS, although the current quality of evidence is still low or 
very low [20,24–27]. 
However, there have been no studies comparing CHM and probio-
tics or synbiotics on the treatment of IBS. The aim of this systematic 
review and meta-analysis was to evaluate the efficacy and safety of 
CHM compared with probiotics or synbiotics for IBS. 
2. Methods 
The protocol of the review was registered in PROSPERO 
(CRD42019133253) on 20th of May 2019 (Available from: http:// 
www.crd.york.ac.uk/PROSPERO/). Different clinical questions could 
be answered by different comparisons: in the comparison of CHM 
versus probiotics, the efficacy of CHM was observed and evaluated; in 
the comparison of CHM combined with probiotics versus probiotics 
alone, the efficacy of CHM as an adjuvant therapy was observed and 
evaluated. Only RCTs of CHM versus probiotics were included in this 
study. A systematic review comparing RCTs of CHM combined with 
probiotics versus probiotics alone has been published previously [28]. 
After the protocol was registered, we made some revisions of the pre-
vious version of the protocol regarding the comments of digestive 
clinical experts. Since psychological states are important factors in the 
occurrence and recurrence of IBS, we expanded the outcomes of relief 
of depression and anxiety as amendments. All the revisions had been 
pre-defined before conducting the review. 
3. Eligibility criteria 
3.1. Type of studies 
RCTs were included in the review, irrespective of blinding, pub-
lication status and language. Randomized cross-over trials were in-
cluded only if the trial reported a wash-out period to eliminate any 
carry-over effects from the first period of treatment before cross-over. 
3.2. Type of participants 
To be included in the review, the diagnosis of IBS had to be based on 
the Manning criteria, the Kruis criteria or the Rome I-IV criteria, but 
there were no restrictions on the patient's age, race or gender. 
3.3. Type of interventions 
The interventions of treatment groups were CHM. These could in-
clude single herbs (or extracts from single herbs), Chinese proprietary 
medicines, or mixtures of several herbs, irrespective of preparation 
(e.g., decoction, oral liquid, tablets, capsules, pills, powders, plasters or 
injections), means of delivery (e.g., oral, intramuscular or intravenous 
injection), dosage, and regimens of herbs. The control interventions 
were probiotics or synbiotics (any dose, strain, species, duration or 
treatment regime) alone. Co-interventions were allowed as long as all 
arms of the randomized allocation received the same co-intervention. 
3.4. Type of outcomes 
The primary outcomes were: (1) global improvements of symptoms: 
including overall symptoms improvement rate and overall symptoms 
scores; (2) quality of life (QOL). The secondary outcomes included: (1) 
relapse rates; (2) the improvement of predominant symptoms: in-
cluding the scores of abdominal pain, distension and diarrhea; (3) 
psychological states: including depression and anxiety; (4) cost-effec-
tiveness; (5) adverse events. The outcomes were measured at the end of 
treatment and at maximal follow-up after completion of the treatment. 
With reference to [29], the overall symptoms improvement rate in 
this study was defined as more than 30 % improvement in overall 
symptoms scores or improved signs and symptoms. Overall symptoms 
improvement rate = [(overall symptoms scores before treatment - 
overall symptoms scores after treatment)/ overall symptoms scores 
after treatment] * 100 %. Overall symptoms scores were defined as: the 
sum of symptom scores of individual symptoms at least including 
diarrhea, abdominal pain and distension; or scores of scales that re-
flected the overall condition of IBS (e.g., IBS-SSS). 
3.5. Search strategy 
The following electronic databases were searched from their in-
ception dates to March 2020: China National Knowledge Infrastructure 
(CNKI), Wanfang database, Chongqing VIP (CQVIP) and SinoMed; Ovid 
MEDLINE, Ovid Embase. Trial registers were also searched: the 
Cochrane Central Register of Controlled Trials (CENTRAL), the 
Cochrane IBD Group Specialized Register, International Standard 
Randomized Controlled Trial Number Register (www.controlled-trials. 
com/), US National Institutes of Health Ongoing Trials Register (www. 
ClinicalTrials.gov) and World Health Organization International 
Clinical Trials Registry (www.who.int/ictrp/en/). In addition, we 
searched the reference lists of all included studies to identify any fur-
ther relevant trials, conference full texts and dissertations. There were 
no restrictions on publication language. For details of the search 
strategy, see Supplementary File 1. 
3.6. Study selection and data extraction 
Two reviewers (FLB and RLC) independently screened and retrieved 
studies by reviewing titles and abstracts. If no decision was made for a 
particular study from the title and abstract, the full text would be 
available for further evaluation. The authors discussed any disagree-
ments in order to reach a consensus, or a third (JPL) was called upon to 
adjudicate. 
Two authors (RLC and ZYL) used standardized tables to extract data 
independently from the included studies. Disagreements were resolved 
through discussion and consultation. If consensus could not be reached, 
the opinion of a third author (HJC) was sought. Duplicate published 
studies were removed. For trials with unclear information, an attempt 
was made to contact the authors for further details. The following data 
were extracted: primary author, funding source, study setting, metho-
dological characteristics, mean age, gender and ethnicity of patients, 
number of randomized patients, reason and number dropped out or lost 
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during follow-up, eligibility criteria, subtype of IBS, the diagnostic 
criteria, type of CHM, route of delivery, dosage, frequency and duration 
of intervention, probiotic/synbiotic strain, species, dosage, frequency 
and duration of intervention, co-interventions, details of the compar-
ison regime, outcome measures (end of treatment and follow-up), and 
number and type of adverse events. Regardless of compliance or follow- 
up, data on the number of patients under each outcomes divided by the 
assigned treatment group was required for an intention-to-treat ana-
lysis. One author (ZYL) entered the data into Review Manager (RevMan 
5.3, 2014) and another (NL) checked it. 
3.7. Quality assessment 
The risk of bias for each study was assessed by two authors (FLB and 
RLC) with the Cochrane risk of bias tool. After arbitration by one author 
(NR), any disagreements were discussed and consensus reached. Each 
domain was judged as ‘low’, ‘high’ or ‘unclear’: (1) random sequence 
generation; (2) allocation concealment; (3) blinding participants and 
evaluators; (4) blinding outcome assessment; (5) incomplete outcome 
data; (6) selective outcome reporting; (7) other bias: including elig-
ibility criteria, baseline and conflicts of interests. 
3.8. Data analysis 
Dichotomous data was presented as risk ratio (RR) and continuous 
outcomes as mean difference (MD), with 95 % confidence intervals (CI). 
Intention-to-treat analyses were performed only for dichotomous out-
comes where possible. For dichotomous outcomes, patients with in-
complete or missing data were included in a sensitivity analysis by 
counting them as treatment failures in order to explore the possible 
effect of loss to follow-up on the findings (‘worst-case’ scenario). 
The χ² test was used to evaluate heterogeneity. A P value of < 0.10 
was considered to be statistically significant. When there was sig-
nificant heterogeneity, the results of I² were quantified for each study 
and interpreted as a percentage of the total variation between studies 
caused by heterogeneity rather than chance [30]. Referring to the Co-
chrane Handbook 5.1.0, we defined I²: < 25 % represented mild het-
erogeneity; 25 %–50 % represented moderate heterogeneity; > 50 % 
represented severe heterogeneity. When more than 75 %, no meta- 
analysis was performed. A random effects model was planned to use 
when the heterogeneity more than 25 %, otherwise the fixed effect 
model was used. Subgroup analysis was employed to explore potential 
sources of heterogeneity. If sufficient data were available, subgroup 
analyses were performed based on the types of probiotic/synbiotic 
strain, species, dose, different diagnostic criteria, duration of treatment 
and type of CHM. Sensitivity analyses were intended to be conducted so 
that robustness can be tested, in terms of random sequence generation 
(low or high) and selective reporting (low or high/unclear). 
If there were at least 10 trials in one meta-analysis, publication bias 
was evaluated by constructing a funnel plot for each outcome. If the 
funnel plot was asymmetric, publication bias may be considered one of 
the reasons for the asymmetry of the funnel plot. 
Trial Sequential Analysis (TSA) (version 0.9.5.10) was applied to 
calculate the required sample size in a meta-analysis and to detect the 
robustness of the results. For dichotomous outcomes, the diversity-ad-
justed required information size (DARIS) was planned to estimate based 
on the event proportion in the control group, a relative risk improve-
ment of 10 %, an alpha of 5 %, a beta of 10 % [31], and diversity 
suggested by the trials in the meta-analysis [32,33]. For continuous 
outcomes, the DARIS was intended to estimate based on the standard 
deviation (SD) observed in the control group; a minimal relevant dif-
ference of 50 % of this SD; an alpha of 5 %; a beta of 10 % [31]; and 
diversity suggested by trials in the meta-analysis [32,33]. 
3.9. Evidence assessment 
The Grades of Recommendations Assessment, Development and 
Evaluation (GRADE) was used to assess the quality of the evidence. We 
judged whether to downgrade the evidence of included RCTs and as-
sessed the evidence as: high, moderate, low or very low. 
4. Results 
4.1. Searching and screening 
A total of 1454 articles were identified and downloaded from 10 
databases (search strategy details in Supplementary File 1). After 
excluding duplicates, 776 articles remained (647 Chinese and 129 
English). After browsing the titles and abstracts and excluding articles 
that did not meet the inclusion criteria, 176 remained. After reading the 
full texts, 47 trials [34–80] (44 Chinese and 3 English) were finally 
included. (Fig. 1) 
4.2. Study characteristics 
Tables 1 and 2 showed the characteristics of the included trials. 
Tang JL 2011 [61] and Han SK 2011 [45] were the same trial, but had 
published different outcomes in two articles. Li DS 2017 [50] was a 
three-arm trial (Modified Buhuanjin Zhengqi San 2 vs Modified Bu-
huanjin Zhengqi San 3 vs triple Bifidobacterium preparations 2). Of the 
47 trials included, 43 were IBS-D, 3 were IBS-C, and 1 was IBS-M. 32 
trials used the Rome III as diagnostic criteria, 13 used Rome II, 1 used 
Rome IV, and 1 used Rome I. Sample sizes ranged from 23 to 175. The 
average age ranged from 18 to 65 years. The course of disease ranged 
from 6 months to 34 years. There were 47 CHM prescriptions involved 
(see Supplementary File 2) in 5 different dosage forms (decoctions, 
granules, bolus, capsules and oral liquids). The 47 CHM prescriptions 
were mainly divided into four categories according to their actions: 
soothing liver and invigorating spleen (SLIS) formulae (12 trials); in-
vigorating spleen and resolving dampness (ISRD) formulae (8 trials); 
soothing liver, invigorating spleen and resolve dampness (SLISRD) 
formulae (4 trials); warming and invigorating spleen and kidney (WISK) 
formulae (6 trials) (and other prescriptions that cannot be categorized, 
17 trials). The control group involved 12 probiotics (10 Chinese pro-
ducts, 1 Korean product and 1 Japanese product). No studies on syn-
biotics met the inclusion criteria. The duration of treatment was from 
0.5 months to 2 months. Of the 47 trials, 44 reported overall symptoms 
improvement rate, 15 reported overall symptoms scores, 5 reported 
relapse rates, 5 reported QOL, 21 reported abdominal pain relief, 13 
reported distension relief, 18 reported diarrhea relief, 1 reported con-
stipation relief, 1 reported depression, 14 reported adverse events, and 
none reported cost-effectiveness. 
4.3. Risk of bias of included trials 
The included trials were judged to have unclear risk of bias in most 
domains. Almost all trials (46/47) had high risk of blinding of partici-
pants and personnel. More than half of the trials (25/47) might have 
high risk of selective reporting (Fig. 2). In the domain of random se-
quence generation, one trial [71] did not mention the recruitment in a 
2:1 ratio, and the final reported number of cases was close to 2:1, which 
was considered to be high risk of bias. Fifteen trials referred to methods 
for generating random sequence with low risk. The rest of the trials had 
an unclear risk, as only the word "random" was mentioned. All trials did 
not describe allocation concealment, resulting in unclear risk. Only one 
trial [35] claimed to be blinded to trial-related personnel (including 
participants, researchers, clinicians, investigators, clinical research co-
ordinator and clinical pharmacist) between the two groups, so both 
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blinding domains were rated low risk. The remaining trials had high 
risk of performance bias due to different dosage forms between the two 
groups, or unclear risk of detection bias due to lack of description of the 
evaluator blinding. In the domain of incomplete outcome data, three 
trials were deemed to have high risk due to a dropout rate of more than 
10 %, and the other three trials had very few dropouts, which were low 
risk. The remaining trials did not mention whether there was attrition 
and was rated as unclear. Twenty-six trials were rated as high bias 
because they did not report any primary outcomes or the necessary 
specific symptoms (diarrhea/constipation, abdominal pain or disten-
sion) that were not contained in the definition of overall symptoms 
improvement rate (or overall symptoms scores). The remaining trials 
had low bias. One trial [35] was considered to have high risk of other 
bias due to funding from pharmaceutical companies. The five trials 
adequately reported for the funding, eligible standard and baseline si-
tuation and have low risk. The remaining trials had high risk due to 
insufficient reporting of the above three sets of data. (Fig. 3) 
4.4. Effects of the interventions 
4.4.1. IBS-D 
Considering the general heterogeneity brought about by the dif-
ferent composition of CHM formulae, we finally adopted the random 
effect model in the meta-analysis. Meta-analysis was conducted only for 
overall symptoms improvement rate and relapse rate. Due to in-
sufficient data, subgroup analysis and sensitivity analysis were only 
performed on overall symptoms improvement rate. 
4.4.2. Primary outcomes 
“4.4.2.1” should be "4.4.1.1.1".4.4.2.1 Global improvements of symptoms 
4.4.2.1.1. Overall symptom improvement rate. A total of 41 trials 
reported overall symptom improvement rate: 1509/1665 (90.6 %) 
participants in CHM group versus 1109/1542 (71.9 %) participants in 
probiotics group. Compared with probiotics, CHM showed certain 
advantages in increasing overall symptom improvement rate (RR 
1.24, 95 % CI 1.18–1.30, I2 = 55 %, 41 trials). (Fig. 4) 
Fig. 1. Flow diagram.  
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4.4.2.1.1.1“4.4.2.1.1.1” should be "①".. Sensitivity analysis 
‘Low risk’ showed that random sequence generation bias did not 
influence the above results (RR 1.21, 95 % CI 1.13–1.29, P = 0.09, I2 = 
37 %, 13 trials, 1153 participants). ‘Low risk’ showed that selective 
reporting bias did not influence the above results (RR 1.24, 95 % CI 
1.13–1.36, P < 0.00001, I2 = 74 %, 18 trials, 1478 participants). 
(Table 3) 
“4.4.2.1.1.2” should be "②".4.4.2.1.1.2. Subgroup analysis 
Due to the significant heterogeneity (I2 = 55 %), subgroup analysis 
was performed according to the registered protocol. 
There was a statistically significant difference between subgroups 
on the effect of CHM on overall symptoms improvement rate, when 
comparing trials with different Rome criteria (test for subgroup 
differences: P < 0.00001, I2 = 92 %; Rome II: RR 1.32, 95 % CI 
1.22–1.43, I2 = 28 %, 1066 participants; Rome III: RR 1.20, 95 % CI 
1.15–1.26, I2 = 28 %, 2041 participants) (Supplementary File 3); 
when comparing trials assessing the duration of treatment within 4 
weeks versus 4 weeks to 6 months (test for subgroup differences: P = 
0.04, I2 = 76.4 %; 4w-6m: RR 1.26, 95 % CI 1.20–1.33, I2 = 44 %, 
2669 participants) (Supplementary File 4); when comparing trials 
assessing single strain versus multi-strain probiotics (test for subgroup 
differences: P = 0.05, I2 = 73.1 %; multi-strain probiotics: RR 1.27, 95 
% CI 1.21–1.32, P < 0.20, I2 = 18 %, 2333 participants) 
(Supplementary File 5); when trials compared SLIS formulae with 
different probiotics (test for subgroup differences: P = 0.002, I2 = 76.8 
%) (Fig. 5). The CHM prescriptions used in the trials included in this 
Table 2 
Composition of probiotics.      
Probiotics Product names Manufacturers Composition and dosage  
triple Bifidobacterium preparations 1 JinShuangQi Inner Mongolia Shuangqi 
Pharmaceutical Co., Ltd., Inner 
Mongolia, China 
Bifidobacterium longum (0.5 × 107 CFU), Lactobacillus bulgaricus 
(0.5 × 106 CFU) and Streptococcus thermophiles (0.5 × 106 CFU) 
triple Bifidobacterium preparations 2 PeiFeiKang Shanghai Xinyi Pharmaceutical Co., Ltd., 
Shanghai, China 
Bifidobacterium (1.0 × 107 CFU), Lactobacillus (1.0 × 107 CFU) 
and Enterococcus (1.0 × 107 CFU) 
triple Bifidobacterium preparations 3 BeiFeiDa Jincheng Haelsth Pharmaceutical Co., 
Ltd., Shanxi, China 
Bifidobacterium longum (1.0 × 106 CFU), Lactobacillus 
acidophilus (1.0 × 106 CFU) and Enterococcus faecalis (1.0 × 106 
CFU) 
Lactobacillus acidophilus preparations YiJunKang Tonghua Golden-horse Pharmaceutical 
Group Co., Ltd., Jilin, China 
Lactobacillus acidophilus (5 × 106) 
Bifidobacterium adolescentis preparations LiZhuChangLe Livzon Pharmaceutical Group Co., Ltd., 
Guangdong, China 
Bifidobacterium adolescentis (0.5 × 108) 
Clostridium Butyricum preparations Miyarisan Miyarisan Pharmaceutical Co., Ltd., 
Nagano, Japan 
Clostridium Butyricum MIYAIRI 588 (0.35 × 106 CFU) 
mixture preparations of 7 probiotics Duolac7s CellBiotechCo.,Ltd., Gimpo, Korea Lactobacillus acidophilus (7 × 108), Lactobacillus plantarum (7 × 
108), Lactobacillus rhamnosus (7 × 108), Bifidobacterium breve (7  
× 108), Bifidobacterium lactis (7 × 108), Bifidobacterium longum 
(7 × 108) and Streptococcus thermophiles (7 × 108) 
quadruple Bifidobacterium infantis 
preparations 
SiLianKang Hangzhou Grand Biologic 
Pharmaceutical INC., Hangzhou, China 
Bifidobacterium infantis (0.5 × 106 CFU), Lactobacillus (0.5 × 106 
CFU), Enterococcus (0.5 × 106 CFU) and Bacillus cereus (0.5 × 105 
CFU) 
Saccharomyces boulardii preparations YiHuo Laboratoires BIOCODEX, France Saccharomyces boulardii (1.3 × 109 CFU/g) 
mixture preparations of Clostridium 
Butyricum and Bifidobacterium 
infantis 
ChangLeKang Shandong Kexing Biological Products 
Co., Ltd., Shandong, China 
Clostridium Butyricum (1.0 × 107 CFU/g) and Bifidobacterium 
infantis (1.0 × 106 CFU/g) 
Bacillus Licheniformis preparations ZhengChangSheng Northeast Pharmaceutical Group Co., 
Ltd., Shenyang, China 
Bacillus Licheniformis (2.5 × 108) 
triple Lactobacillus preparations JuKe Jiangsu Meitong Pharmaceutical Co., 
Ltd., Jiangsu, China 
Lactobacillus lactis (≥70), Lactobacillus acidophilus (≥7 × 103) 
and Streptococcus lactis(≥1.4 × 104) 
mixture preparations of Bacillus Subtilis 
and Enterococcus Faecium 
MeiChangAn Beijing Hanmei Pharmaceutical Co., Ltd., 
Beijing, China 
Bacillus Subtilis R-179 (5.0 × 107) and Enterococcus Faecium R- 
026 (4.5 × 108) 
Fig. 2. Risk of bias graph.  
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study could be mainly divided into four categories according to their 
actions: SLIS formulae; ISRD formulae; SLISRD formulae; WISK for-
mulae. Subgroup analysis based on the same type of formulae with the 
same probiotics showed that SLIS formulae might be better than triple 
Bifidobacterium preparations 2 for improving the overall symptoms of 
IBS-D (RR 1.33, 95 % CI 1.20–1.47, P < 0.51, I2 = 0 %, 6 trials, 476 
participants) (Fig. 5). 
However, it must be recognized that the quality of the evidence in 
the above subgroups analysis was very low (Table 6). 
“4.4.2.1.1.3” should be "③".4.4.2.1.1.3. Trial sequential analysis 
The DARIS was calculated to be 3584 participants, based on an 
event rate in the control group of 72.8 %, a risk ratio reduction (RRR) of 
10 %, a two-sided alpha of 5.0 %, a beta of 10 %, and observed diversity 
of 60 %. TSA showed that the Z-curve crossed the benefit boundary but 
did not reach the required information size. This indicates that CHM 
versus probiotics results in a 10 % or greater RRR among IBS-D. The 
TSA-adjusted CI was 1.17 to 1.31. (Fig. 6) 
“4.4.2.1.1.4” should be "④".4.4.2.1.1.4. Publication Bias 
There were some signs of asymmetry in the visual inspection of the 
funnel plot, indicating a high risk of publication bias. (Fig. 7) 
“4.4.2.1.1.5” should be "⑤".4.4.2.1.1.5. Quality of the evidence 
Summary of findings for the overall symptoms improvement rate 
provides detailed information on the evidence assessment. The results 
of several subgroup analyses had very low quality evidence. (Table 6) 
4.4.2.1.2. Overall symptoms scores. Fifteen trials 
[35,39,41,50,52,53,56–59,61,64,68,74,79] reported overall symptoms 
scores, and meta-analysis was not performed given that they used 
different custom scoring criteria. Twelve trials favored CHM to reduce 
overall symptoms scores (but three of them [35,39,79] showed no 
statistical difference between two groups). Almost all of the trials were 
small sample sizes (Table 4). 
4.4.2.2. “4.4.2.2” should be "4.4.1.1.2". Quality of life. Only one trial 
[58] reported that a modified Tongxie Yaofang could reduce the total 
score of IBS-QOL scale by 32.96 (RR 32.96, 95 % CI 4.64–61.28) 
compared with triple Bifidobacterium preparations 2. 
4.4.3. Secondary outcomes 
“4.4.3.1” should be "4.4.1.2.1".4.4.3.1 Relapse rates. Five trials reported 
relapse rates. Considering the insufficient data, subgroup analysis and 
sensitivity analysis were not meaningful (Fig. 8), although the results 
showed that CHM might reduce the relapse rate to 27 % compared with 
probiotics (RR 0.27, 95 % CI 0.18−0.40, 5 trials, 382 participants). The 
follow-up time points of the five trials were all different (After the trial: 
Li CY 2012 [49]: 1st month, Liu F 2015 [53]: 3rd month, Rao J 2010 
[59]: 2nd month, Yang F 2009 [71]: 8th month, Yin LJ 2002 [72]: 6th 
month), and the results were interpreted with caution due to their 
clinical heterogeneity. 
4.4.3.1.0.1. Quality of the evidence. The certainty of evidence for 
relapse rate was defined as very low. (Table 6) 
“4.4.3.2” should be "4.4.1.2.2".4.4.3.2 Predominant symptom relief. Due 
to the significant differences in the scoring criteria, no meta-analysis 
were performed for the following outcomes. The results of qualitative 
synthesis are shown in Tables 4 and 5. 
4.4.3.2.1. Abdominal pain relief. “4.4.3.2.1.1” should be 
"①".4.4.3.2.1.1. Effective rate of abdominal pain relief 
Six studies [52,62,70,74–76] reported improvement in abdominal 
pain in the form of ratios (Table 5). No significant statistical differences 
between the two groups were found in the two trials. Although the four 
trials [52,70,75,76] supported CHM, limited to the small sample size 
and nearly invalid CI lower limit, this result should be treated with 
caution. 
“4.4.3.2.1.2” should be "②".4.4.3.2.1.2. Abdominal pain scores 
17 trials [35,36,39,41,44,45,50,51,57–59,61,64,66,74,79] mea-
sured abdominal pain scores. In the CHM group, abdominal pain was 
Fig. 3. Risk of bias of summary.  
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relieved to varying degrees, but 8 studies [35,36,39,41,45,50,51,61] 
did not demonstrate statistically significant differences between two 
groups (Table 4). 
4.4.3.2.2. Distension relief. “4.4.3.2.2.1” should be "①".4.4.3.2.2.1. 
Effective rate of distension relief 
Five trials [52,62,70,75,76] measured changes of distension in the 
form of ratios. Although each trial showed that CHM could relieve 
abdominal pain to varying degrees, the lower CI limits for all trials were 
close to the invalid line, and there was no statistically significant dif-
ference between the two groups in one trial [76]. (Table 5) 
"4.4.3.2.2.2” should be "②".4.4.3.2.2.2. Distension scores 
Nine trials [35,45,51,57–59,61,64,79] measured distension scores. 
Four trials [35,51,57,79] showed no statistical difference between CHM 
and probiotics, and the lower limit of the four RR was close to the in-
effective line. (Table 4) 
4.4.3.2.3. Diarrhea relief. "4.4.3.2.3.1” should be "①".4.4.3.2.3.1. 
Effective rate of diarrhea frequency relief 
Four trials [45,52,61,70] measured changes of diarrhea frequency 
in the form of effective rates. One study had reported different out-
comes in two separate articles [45,61]. Although each trial showed that 
CHM could alleviate the frequency of diarrhea in different degrees, 
there was no statistical difference in one trial [45,61], and the lower 
limit of CI in one trial [52] was almost close to the invalid line. 
(Table 5) 
4.4.3.2.3.2“4.4.3.2.3.2” should be "②".. Diarrhea frequency scores 
Seven trials [39,41,44,50,58,64,66] measured the scores of diarrhea 
frequency. Although each trial showed that CHM reduced frequency 
scores to varying degrees, five trials [39,41,44,50,66] showed no sta-
tistical difference between two groups. (Table 4) 
“4.4.3.2.3.3” should be "③".4.4.3.2.3.3. Effective rate of improve-
ment in stool consistency 
Four trials [45,52,61,70] reported changes of the stool consistency 
in the form of effective rates. Although the trials showed that the stool 
consistency were relieved to varying degrees, two trials [45,61] were 
not statistically different between two groups, and the CI lower limit of 
one trial [52] was nearly ineffective. (Table 5) 
“4.4.3.2.3.4” should be "④".4.4.3.2.3.4. Stool consistency scores 
Seven trials [39,41,44,50,57,64,66] reported stool consistency 
scores. Although each trial showed a reduction in stool consistency 
scores to varying degrees, three trials showed no statistical difference 
Fig. 4. Forest plot of overall symptoms improvement rate.  
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Table 3 
Summary of findings for IBS RCTs comparison of CHM vs probiotics.     
Study ID Participants RR[95 %CI] or MD[95 
%CI]  
IBS-D 
Overall symptoms improvement rate 
Bian YJ 2017 60 1.24 [0.94, 1.63] 
Cai T 2012 83 1.46 [1.14, 1.87] 
Chen YB 2015 66 1.15 [0.93, 1.41] 
Ding ZY 2015 72 1.21 [1.02, 1.43] 
Dong GF 2014 70 1.10 [0.92, 1.32] 
Du YJ 2016 60 1.07 [0.94, 1.23] 
Gao Y 2013 119 1.21 [1.01, 1.45] 
Gong JH 2013 98 1.33 [1.04, 1.71] 
Guo JX 2016 71 1.26 [0.98, 1.60] 
Guo YC 2013 60 1.00 [0.91, 1.10] 
He L 2012 66 1.18 [0.97, 1.44] 
Hu LJ 2014 100 1.55 [1.24, 1.94] 
Hu W 2006 85 1.37 [1.06, 1.77] 
Li CY 2012 175 1.56 [1.28, 1.89] 
Li DS 2017 (a) 60 1.17 [0.93, 1.48] 
Li DS 2017 (b) 60 1.22 [0.98, 1.52] 
Li JH 2012 60 1.04 [0.80, 1.36] 
Li QJ 2015 70 1.26 [1.00, 1.59] 
Liu F 2015 71 1.34 [1.05, 1.71] 
Luo CM 2007 69 1.24 [0.97, 1.57] 
Meng YB 2009 60 1.40 [1.07, 1.83] 
Miao C 2012 60 1.56 [1.14, 2.12] 
Pan F 2009 117 0.98 [0.88, 1.10] 
Qiao HJ 2015 86 1.19 [0.97, 1.46] 
Rao J 2010 60 1.35 [1.02, 1.79] 
Tang JL 2011, Han SK 2011 80 1.11 [0.85, 1.44] 
Wang HL 2006 60 1.44 [1.04, 2.00] 
Wang JY 2008 100 1.24 [1.04, 1.47] 
Wen TY 2016 120 1.16 [1.03, 1.31] 
Wu HQ 2015 100 1.24 [1.04, 1.47] 
Wu WB 2012 63 1.28 [0.99, 1.64] 
Xu XT 2009 120 1.23 [1.03, 1.46] 
Xu YJ 2015 80 1.50 [1.14, 1.97] 
Yang F 2009 86 1.74 [1.25, 2.43] 
Yao M 2002 64 1.15 [0.91, 1.45] 
Yin LJ 2002 100 0.98 [0.89, 1.07] 
Yu C 2013 60 1.60 [1.07, 2.39] 
Yu HT 2007 60 1.09 [0.84, 1.40] 
Yu SL 2007 76 1.31 [1.05, 1.65] 
Zhang SS 2004 72 1.45 [1.09, 1.93] 
Zhao CX 2015 69 1.30 [1.02, 1.65] 
Zhou SF 2016 40 1.13 [0.86, 1.46] 
Zhuang YH 2005 23 1.01 [0.78, 1.30]  
Overall symptoms scores 
Ding ZY 2015 72 −2.52 [−5.14, 0.10] 
Du YJ 2016 60 −2.54 [−3.65, −1.43] 
Guo YC 2013 60 −3.80 [−5.10, −2.50] 
Li DS 2017 (a) 60 −3.17 [−4.86, −1.47] 
Li DS 2017 (b) 60 −3.60 [−5.26, −1.94] 
Liu F 2015 71 −2.17 [−3.87, −0.47] 
Miao C 2012 60 −3.37 [−5.18, −1.56] 
Pan F 2009 117 0.20 [0.09, 0.31] 
Qiao HJ 2015 86 −48.49 [−74.02, −22.96] 
Rao J 2010 60 −7.10 [−10.21, −3.99] 
Wang W 2018 80 −2.07 [−3.09, −1.05] 
Wu WB 2012 70 −1.22 [−2.32, −0.12] 
Yu C 2013 60 −4.27 [−7.04, −1.50] 
Zhou SF 2016 40 −0.80 [−3.63, 2.03]  
QOL 
Qiao HJ 2015 86 32.96 [4.64, 61.28]  
Relapse rate 
Li CY 2012 175 0.29 [0.16, 0.52] 
Liu F 2015 8 0.60 [0.06, 6.44] 
Rao J 2010 47 0.44 [0.12, 1.65] 
Yang F 2009 67 0.19 [0.06, 0.58] 
Yao M 2002 53 0.23 [0.07, 0.74] 
Yin LJ 2002 85 0.19 [0.08, 0.46]   
Table 3 (continued)    
Study ID Participants RR[95 %CI] or MD[95 
%CI]  
Effective rate of abdominal pain relief 
Guo YC 2013 60 1.07 [0.94, 1.23] 
Li QJ 2015 51 1.39 [1.03, 1.88] 
Wang HL 2006 55 1.25 [0.98, 1.60] 
Xu YJ 2015 73 1.95 [1.38, 2.77] 
Yu C 2013 60 1.04 [0.92, 1.16] 
Yu SL 2007 71 1.32 [1.06, 1.65] 
Zhang SS 2004 65 1.32 [1.02, 1.71]  
Abdominal pain scores 
Bian YJ 2017 60 −0.30 [−0.79, 0.19] 
Ding ZY 2015 72 −0.19 [−0.87, 0.49] 
Du YJ 2016 60 0.00 [−0.41, 0.41] 
Guo JX 2016 71 −0.37 [−0.71, −0.03] 
Guo YC 2013 60 −0.57 [−0.86, −0.28] 
Li DS 2017 (a) 60 −0.47 [−0.93, −0.00] 
Li DS 2017 (b) 60 −0.73 [−1.14, −0.33] 
Li JH 2012 60 −0.14 [−0.72, 0.44] 
Pan F 2009 117 0.12 [0.01, 0.23] 
Qiao HJ 2015 86 −11.62 [−17.06, −6.18] 
Rao J 2010 60 −0.87 [−1.25, −0.49] 
Tang JL 2011, Han SK 2011 80 −0.04 [−0.21, 0.13] 
Wang W 2018 80 −1.78 [−1.96, −1.60] 
Wen TY 2016 122 −0.72 [−0.77, −0.67] 
Yu C 2013 60 −0.56 [−0.98, −0.14] 
Zhou SF 2016 40 −0.90 [−1.77, −0.03]  
Effective rate of distension relief 
Li QJ 2015 41 1.59 [1.10, 2.30] 
Wang HL 2006 51 1.63 [1.11, 2.40] 
Xu YJ 2015 38 3.70 [1.21, 11.38] 
Yu SL 2007 74 1.26 [1.03, 1.55] 
Zhang SS 2004 57 1.23 [0.95, 1.60]  
Distension scores 
Guo YC 2013 60 Not estimable 
Li JH 2012 60 0.04 [−0.57, 0.65] 
Pan F 2009 117 0.07 [−0.03, 0.17] 
Qiao HJ 2015 86 −8.14 [−13.53, −2.75] 
Rao J 2010 60 −0.80 [−1.18, −0.42] 
Tang JL 2011, Han SK 2011 80 −0.34 [−0.59, −0.09] 
Wang W 2018 80 −0.30 [−0.47, −0.13] 
Zhou SF 2016 40 0.45 [−0.37, 1.27]  
Diarrhea frequency scores 
Ding ZY 2015 72 −0.65 [−1.05, −0.25] 
Du YJ 2016 60 −0.20 [−0.53, 0.13] 
Guo JX 2016 71 −0.26 [−0.56, 0.04] 
Li DS 2017 (a) 60 −0.27 [−0.61, 0.08] 
Li DS 2017 (b) 60 −0.27 [−0.61, 0.08] 
Qiao HJ 2015 86 −0.65 [−1.02, −0.28] 
Wang W 2018 80 −0.45 [−0.61, −0.29] 
Wen TY 2016 122 −0.06 [−0.12, 0.00]  
Effective rate of diarrhea frequency relief 
Li QJ 2015 70 1.38 [1.06, 1.79] 
Tang JL 2011, Han SK 2011 80 1.09 [0.76, 1.56] 
Xu YJ 2015 62 1.89 [1.28, 2.80]  
Stool consistency scores 
Ding ZY 2015 72 −0.74 [−1.32, −0.16] 
Du YJ 2016 60 −0.40 [−0.90, 0.10] 
Guo JX 2016 71 −0.26 [−0.61, 0.09] 
Li DS 2017 (a) 60 −0.87 [−1.32, −0.42] 
Li DS 2017 (b) 60 −0.67 [−1.18, −0.15] 
Pan F 2009 117 −0.02 [−0.15, 0.11] 
Wang W 2018 80 −0.36 [−0.56, −0.16] 
Wen TY 2016 122 −0.74 [−0.79, −0.69]  
Effective rate of stool consistency relief 
Li QJ 2015 62 1.32 [1.03, 1.69] 
Tang JL 2011, Han SK 2011 80 1.53 [1.00, 2.34] 
Xu YJ 2015 73 2.47 [1.58, 3.87]  
(continued on next page) 
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between the two groups. The forest plot showed a large heterogeneity 
between trials. (Table 4) 
“4.4.3.2.3.5” should be "⑤".4.4.3.2.3.5. Effective rate of diarrhea 
(not distinguishing between frequency or consistency) relief 
Four trials [62,74–76] reported the effective rate of diarrhea. Only 
one trial [74] showed a positive result for CHM, and the remaining 
trials showed no significant statistical difference between the two 
groups. (Table 5) 
“4.4.3.2.3.6” should be "⑥".4.4.3.2.3.6. Diarrhea scores (not distin-
guishing between frequency or consistency) 
Nine trials [36,38,45,51,59,61,67,74,79] reported diarrhea scores. 
The trials showed that CHM could reduce the diarrhea scores to varying 
degrees, but five trials [36,38,45,51,61] showed no significant statis-
tical difference between the two groups. (Table 4) 
4.4.3.3. “4.4.3.3” should be "(4)". Psychological states and cost- 
effectiveness. None of trials for IBS-D reported the outcome of 
psychological states and cost-effectiveness. 
“4.4.3.4” should be "(5)".4.4.3.4 Adverse events. Thirteen trials 
[35,36,38,39,41,48,50,51,54,55,58,59,74] reported adverse events, 
11 [36,38,39,41,48,50,51,54,58,59,74] of which claimed no adverse 
events in both groups, and 2 [35,55] reported detailed types and case 
number of adverse events, mainly for gastrointestinal symptoms such as 
constipation (Table 1). 
4.4.4. Summary of findings table 
Only overall improvement rate of symptoms and relapse rate were 
evaluated by GRADE (See Table 6). For the evaluation of the subgroup 
results for overall symptoms improvement rate see Supplementary 
File 6. 
4.5. 4.4.2 IBS-C 
Meta-analysis was only performed for overall symptoms improve-
ment rate [60,65]. There was no statistically significant difference be-
tween CHM and probiotics in improving overall symptoms improve-
ment rate for IBS-C (RR 1.19, 95 % CI 0.86–1.63, P = 0.09, I2 = 66 %, 
2 trials, 136 participants). Al-Jassim ZG 2019 [34] showed that ginger 
was less effective in relieving abdominal pain, distension and con-
stipation than Brewer’ s yeast at 20 days after treatment. Wang XJ 2019 
[65] showed that Dachaihu Tang might be able to lower the HADS score 
more than triple Bifidobacterium preparations 1, but the difference was 
not statistically significant. (Table 7) 
4.6. 4.4.3 IBS-M 
Only one trial [78] reported overall symptoms improvement rate. 
The results based on a very small sample size (I/C 30/30) showed that 
modified Tongxie Yaofang might be superior to Bacillus Licheniformis 
preparations in improving the overall symptoms of IBS-M (RR 1.47, 95 
% CI 1.10–1.97). 
5. Discussion 
5.1. Summary of main results 
Of the 47 RCTs (3551 participants) included in this systematic re-
view, most used self-customized and composite outcome measure-
ments. Almost all of the trials reported overall symptoms improvement 
rate (44/47), which was a composite outcome. However, there were 
fewer studies concerned with QOL (5/47), relapse rate (5/47), relief of 
specific symptoms (abdominal pain (21/47), distension (13/47), diar-
rhea (18/47), or constipation (1/47), psychological states (1/47), ad-
verse events (14/47) and health economic indicators (0/47). Meta- 
analysis, subgroup analysis and sensitivity analysis were conducted on 
overall symptoms improvement rate. Only meta-analysis was per-
formed on relapse rate. Unclear risk of bias was in almost domains of 
included trials. The high risk of blinding participants and personnel 
existed in almost all trials, and the high risk of selective reporting was 
present in more than half of the trials. In general, very low quality 
evidence showed that CHM might be superior to probiotics in alle-
viating overall symptoms and reducing relapse rates for IBS-D. Due to 
the small number and sample size of included studies on IBS-C and IBS- 
M, there was limited evidence of the efficacy of CHM versus probiotics 
for IBS-C and IBS-M. 
5.2. Compared with previous studies 
Although there was evidence of CHM [21–27] for IBS or probiotics 
for IBS [81–87], no direct evidence to evaluate CHM and probiotics for 
Table 3 (continued)    
Study ID Participants RR[95 %CI] or MD[95 
%CI]  
Diarrhea scores (not distinguishing between frequency or consistency) 
Bian YJ 2017 60 −0.18 [−0.70, 0.34] 
Chen YB 2015 66 −0.16 [−0.51, 0.19] 
Guo YC 2013 60 −0.30 [−0.56, −0.04] 
Li JH 2012 60 −0.10 [−0.98, 0.78] 
Rao J 2010 60 −0.94 [−1.37, −0.51] 
Tang JL 2011, Han SK 2011 80 −0.02 [−0.26, 0.22] 
Wu HQ 2015 100 −0.88 [−1.24, −0.52] 
Yu C 2013 60 −0.60 [−1.04, −0.16] 
Zhou SF 2016 40 −1.20 [−2.09, −0.31]  
Effective rate of diarrhea relief (not distinguishing between frequency or 
consistency) 
Guo YC 2013 60 1.04 [0.92, 1.16] 
Wang HL 2006 60 1.04 [0.89, 1.21] 
Yu C 2013 60 1.61 [1.19, 2.17] 
Yu SL 2007 76 1.29 [1.00, 1.66] 
Zhang SS 2004 72 0.97 [0.83, 1.13]  
Depression scores 
Guo YC 2013 60 −3.29 [−6.16, −0.42]  
Anxiety scores 
Guo YC 2013 60 −5.34 [−8.27, −2.41]  
IBS-C 
Overall symptoms improvement rate 
Wang XJ 2019 60 1.04 [0.84, 1.29]  
Abdominal pain scores 
Al-Jassim ZG 2019 30 5.07 [2.95, 7.19]  
Distension scores 
Al-Jassim ZG 2019 30 5.00 [2.82, 7.18]  
Constipation scores 
Al-Jassim ZG 2019 30 6.20 [4.04, 8.36]  
Depression scores 
Wang XJ 2019 60 −1.00 [−2.48, 0.48]  
IBS-M 
Overall symptoms improvement rate 
Li XY 2011 56 1.52 [1.10, 2.09] 
Zhao JP 2012 60 1.47 [1.10, 1.97]  
Overall symptoms scores 
Li XY 2011 56 −4.70 [−6.55, −2.85]  
Stool consistency scores 
Li XY 2011 56 −0.49 [−1.23, 0.25]  
Effective rate of stool consistency relief 
Li XY 2011 56 1.99 [1.18, 3.37] 
F.-L. Bu, et al.   European Journal of Integrative Medicine 38 (2020) 101177
12
IBS was identified. But high quality original studies and systematic 
reviews comparing CHM with placebo and probiotics with placebo were 
searched for indirect evidence. A primary study [88] published in 
JAMA showed that standard CHM formula (a modified Tongxie Yao-
fang) was significantly beneficial for improving overall symptoms of 
IBS compared with placebo (RR 2.15, 95 %CI 1.26–3.65). A systematic 
review [19] including 19 RCTs showed that probiotics significantly 
improved overall symptoms of IBS over placebo (RR 1.59, 95 %CI 
1.33–1.89). Based on the above indirect comparisons, the difference of 
RR between CHM and probiotics in improving overall symptoms is 
about 0.56. This is quite different from the results of this study (SLIS vs 
triple Bifidobacterium preparations 2 for IBS-D, overall symptoms im-
provement rate: RR 1.33). This may be due to the fact that the results of 
the study [19] are based on multiple IBS subtypes patients and a variety 
of probiotics, which may make the results from indirect comparisons 
less reliable than this study. 
5.3. Limitations 
Race [89,90], age [91,92], diet [93,94] and concomitant medica-
tions (such as antibiotics and antacids) [95] during the trial which may 
have an effect on intestinal flora were not investigated. This could be a 
potential confounder due to lack of reported dietary and medication 
data. The probiotics involved were almost all Chinese products of mixed 
strain preparations, which may conceal or even confuse the effect of 
individual strain but may also limit the international promotion of these 
results. The included trials mostly used composite outcomes, which 
makes it impossible to answer whether CHM or probiotics effect specific 
symptoms. 
Although we have used a random effects model to pool data to avoid 
overestimating the efficacy, included trials are almost all performed in 
China which supports CHM. This may have exaggerated the actual ef-
ficacy of CHM. Probiotics may only be used alone in clinical trials, 
Fig. 5. Forest plot of subgroup analysis according to SLIS formulae for overall symptoms improvement rate.  
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however in clinical practice, they are often used as complementary 
medicines in combination with other conventional medicines. 
The CHM formulae involved in this study were divided into four 
categories according to their core composition and the efficacy, but 
they were completely different. According to the CHM, efficacy, dura-
tion and frequency of administration, clinical effectiveness will vary 
greatly. So the resulting clinical heterogeneity cannot be ignored. More 
importantly, the difference in underlying etiologies is one of the im-
portant potential sources of heterogeneity in the population. 
Unfortunately, the design of the included trials failed to further report 
some data that could reflect this heterogeneity, so these results may still 
have a confounding effect. 
5.4. Implications for future research 
Future research should try to recruit patients based on different 
etiologies and IBS subtypes, involving all ages, especially children and 
the elderly. Data on relevant confounding factors (such as diet and 
concomitant medications) during the trial should be recorded and 
reported. For setting outcomes, more attention should be paid to in-
dividual symptoms, psychological state, adverse events and health 
economics. For measuring outcomes, internationally recognized scales 
(especially Patient-Reported Outcome scales) should be used, such as 
IBS-SSS, IBS-QOL, HAMA and HAMD. In order to focus on long-term 
efficacy and safety, the trial should be conducted for at least 6 months. 
It is essential to pre-register a protocol and report it in any publication. 
The generation and concealment of random sequences and the im-
plementation of blinding methods should be adequately reported. The 
composition and dosage of CHM and probiotics should also be reported 
in detail. Multi-center, multi-ethnic, large-sample, well-designed clin-
ical trials should be conducted in the future. Although the results of TSA 
did not reach the required information size, the Z-curve crossed the 
benefit boundary. It suggested that no more studies were needed. But 
considering the low quality of the included studies, more studies and 
larger sample sizes are still needed in the future. 
5.5. Implications for clinical practice 
Limited data from the subgroup analysis showed that SLIS formulae 
may not be inferior to triple Bifidobacterium preparations (composi-
tion: Bifidobacterium, Lactobacillus and Enterococcus) for improving 
the overall symptoms of IBS-D. The typical representative of the SLIS 
formula is Tongxie Yaofang (composition: Atractylodis Macrocephalae 
Rhizoma, Paeoniae Radix Alba, Citri Reticulatae Pericarpium, and 
Saposhnikoviae Radix). 
6. Conclusions 
Very low quality evidence suggests that CHM may be better than 
probiotics when the duration of treatment lasted more than 4 weeks 
and SLIS formulae may be better than triple Bifidobacterium prepara-
tions for improving the overall symptoms of IBS-D; and some CHM may 
be more advantageous for reducing relapse rates of IBS-D than pro-
biotics, but this needs to be confirmed by large sample size trials in the 
future, and it is not clear which categories of formula is more ad-
vantageous than which probiotics. Although individual studies have 
Fig. 6. Trial Sequential Analysis on overall symptoms improvement rate for IBS-D (41 trials).  
Fig. 7. Funnel plot for overall symptoms improvement rate (41 studies).  
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Table 4 
Effect size of other continuous outcomes.           
Study CHM  Probiotics Mean Difference [95 %CI] 
Mean SD Total  Mean SD Total  
Overall symptomsscores 
Ding ZY 2015 2.57 4.28 36 5.09 6.77 36 −2.52 [−5.14, 0.10] 
Du YJ 2016 3.13 1.74 30 5.67 2.58 30 −2.54 [−3.65, −1.43] 
Ko SJ 2013 30.98 17.43 14 31.55 17.98 14 −0.57 [−13.69, 12.55] 
Li DS 2017 (a) 4.7 3.45 30 7.867 3.256 30 −3.17 [−4.86, −1.47] 
Li DS 2017 (b) 4.267 3.3 30 7.867 3.256 30 −3.60 [−5.26, −1.94] 
Liu F 2015 4.83 3.3 36 7 3.96 35 −2.17 [−3.87, −0.47] 
Miao C 2012 3.3 3.053 30 6.67 4.037 30 −3.37 [−5.18, −1.56] 
Pan F 2009 10.06 0.23 77 9.86 0.32 40 0.20 [0.09, 0.31] 
Qiao HJ 2015 85.23 63.13 43 133.72 57.52 43 −48.49 [−74.02, −22.96] 
Rao J 2010 3.4 3.93 30 10.5 7.76 30 −7.10 [−10.21, −3.99] 
Wang W 2018 5.46 2.21 40 7.53 2.44 40 −2.07 [−3.09, −1.05] 
Wu WB 2012 1.84 2.14 35 3.06 2.54 35 −1.22 [−2.32, −0.12] 
Yu C 2013 4.4 4.056 30 8.67 6.609 30 −4.27 [−7.04, −1.50] 
Zhou SF 2016 8.2 4.77 20 9 4.34 20 −0.80 [−3.63, 2.03]  
Abdominal pain scores 
Bian YJ 2017 0.67 0.84 30 0.97 1.07 30 −0.30 [−0.79, 0.19] 
Ding ZY 2015 1.15 1.44 36 1.34 1.51 36 −0.19 [−0.87, 0.49] 
Du YJ 2016 0.4 0.814 30 0.4 0.814 30 0.00 [−0.41, 0.41] 
Guo JX 2016 0.79 0.729 34 1.16 0.727 37 −0.37 [−0.71, −0.03] 
Ko SJ 2013 27.97 18.35 14 28.45 18.55 14 −0.48 [−14.15, 13.19] 
Li DS 2017 (a) 1.4 1.192 30 1.867 0.507 30 −0.47 [−0.93, 0.00] 
Li DS 2017 (b) 1.133 1.008 30 1.867 0.507 30 −0.73 [−1.14, −0.33] 
Li JH 2012 2.63 1.13 30 2.77 1.17 30 −0.14 [−0.72, 0.44] 
Pan F 2009 2.82 0.38 77 2.7 0.24 40 0.12 [0.01, 0.23] 
Qiao HJ 2015 11.05 13.7 43 22.67 11.97 43 −11.62 [−17.06, −6.18] 
Rao J 2010 0.2 0.55 30 1.07 0.91 30 −0.87 [−1.25, −0.49] 
Tang JL 2011, Han SK 2011 0.85 0.42 40 0.89 0.37 40 −0.04 [−0.21, 0.13] 
Wang W 2018 1.21 0.56 40 2.99 0.15 40 −1.78 [−1.96, −1.60] 
Wen TY 2016 0.77 0.09 61 1.49 0.18 61 −0.72 [−0.77, −0.67] 
Yu C 2013 0.37 0.49 30 0.93 1.081 30 −0.56 [−0.98, −0.14] 
Zhou SF 2016 1.4 1.31 20 2.3 1.49 20 −0.90 [−1.77, −0.03]  
Distension scores 
Ko SJ 2013 25.65 15.1 14 31.81 18.4 14 −6.16 [−18.63, 6.31] 
Li JH 2012 1.47 1.22 30 1.43 1.19 30 0.04 [−0.57, 0.65] 
Pan F 2009 2.65 0.29 77 2.58 0.26 40 0.07 [−0.03, 0.17] 
Qiao HJ 2015 11.63 13.75 43 19.77 11.65 43 −8.14 [−13.53, −2.75] 
Rao J 2010 0.33 0.61 30 1.13 0.86 30 −0.80 [−1.18, −0.42] 
Tang JL 2011, Han SK 2011 0.83 0.58 40 1.17 0.54 40 −0.34 [−0.59, −0.09] 
Wang W 2018 0.92 0.31 40 1.22 0.46 40 −0.30 [−0.47, −0.13] 
Zhou SF 2016 1.85 0.99 20 1.4 1.6 20 0.45 [−0.37, 1.27]  
Diarrhea frequency scores 
Ding ZY 2015 0.45 0.13 36 1.1 1.21 36 −0.65 [−1.05, −0.25] 
Du YJ 2016 0.13 0.507 30 0.33 0.758 30 −0.20 [−0.53, 0.13] 
Guo JX 2016 0.71 0.579 34 0.97 0.726 37 −0.26 [−0.56, 0.04] 
Li DS 2017 (a) 0.133 0.507 30 0.4 0.814 30 −0.27 [−0.61, 0.08] 
Li DS 2017 (b) 0.133 0.507 30 0.4 0.814 30 −0.27 [−0.61, 0.08] 
Qiao HJ 2015 1.72 0.77 43 2.37 0.95 43 −0.65 [−1.02, −0.28] 
Wang W 2018 1.02 0.34 40 1.47 0.38 40 −0.45 [−0.61, −0.29] 
Wen TY 2016 1.49 0.17 61 1.55 0.18 61 −0.06 [−0.12, 0.00]  
Stool consistency scores 
Ding ZY 2015 0.31 0.93 36 1.05 1.52 36 −0.74 [−1.32, −0.16] 
Du YJ 2016 0.73 0.98 30 1.13 1.001 30 −0.40 [−0.90, 0.10] 
Guo JX 2016 0.79 0.77 34 1.05 0.743 37 −0.26 [−0.61, 0.09] 
Li DS 2017 (a) 0.333 0.758 30 1.2 0.997 30 −0.87 [−1.32, −0.42] 
Li DS 2017 (b) 0.533 1.042 30 1.2 0.997 30 −0.67 [−1.18, −0.15] 
Pan F 2009 2.46 0.28 77 2.48 0.36 40 −0.02 [−0.15, 0.11] 
Wang W 2018 1.17 0.49 40 1.53 0.4 40 −0.36 [−0.56, −0.16] 
Wen TY 2016 0.85 0.1 61 1.59 0.17 61 −0.74 [−0.79, −0.69]  
Diarrhea scores (not distinguishing between frequency or consistency) 
Bian YJ 2017 1.27 0.83 30 1.45 1.2 30 −0.18 [−0.70, 0.34] 
Chen YB 2015 0.85 0.61 36 1.01 0.81 30 −0.16 [−0.51, 0.19] 
Li JH 2012 3.9 1.69 30 4 1.8 30 −0.10 [−0.98, 0.78] 
Rao J 2010 0.13 0.43 30 1.07 1.11 30 −0.94 [−1.37, −0.51] 
Tang JL 2011, Han SK 2011 0.87 0.71 40 0.89 0.31 40 −0.02 [−0.26, 0.22] 
Wu HQ 2015 0.86 0.88 50 1.74 0.94 50 −0.88 [−1.24, −0.52] 
Yu C 2013 0.3 0.651 30 0.9 1.029 30 −0.60 [−1.04, −0.16] 
Zhou SF 2016 1.1 1.02 20 2.3 1.75 20 −1.20 [−2.09, −0.31]    
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Fig. 8. Forest plot of relapse rates for IBS-D.  
Table 5 
Effect size of other dichotomous outcomes.        
Study CHM Probiotics Risk Ratio [95 %CI] 
Events Total Events Total  
Effective rate of abdominal pain relief 
Li QJ 2015 25 27 16 24 1.39 [1.03, 1.88] 
Wang HL 2006 26 28 20 27 1.25 [0.98, 1.60] 
Xu YJ 2015 36 38 17 35 1.95 [1.38, 2.77] 
Yu C 2013 29 30 28 30 1.04 [0.92, 1.16] 
Yu SL 2007 34 36 25 35 1.32 [1.06, 1.65] 
Zhang SS 2004 30 33 22 32 1.32 [1.02, 1.71]  
Effective rate of distension 
Li QJ 2015 20 21 12 20 1.59 [1.10, 2.30] 
Wang HL 2006 22 25 14 26 1.63 [1.11, 2.40] 
Xu YJ 2015 10 18 3 20 3.70 [1.21, 11.38] 
Yu SL 2007 36 38 27 36 1.26 [1.03, 1.55] 
Zhang SS 2004 25 28 21 29 1.23 [0.95, 1.60]  
Effective rate of diarrhea frequency relief 
Li QJ 2015 34 37 22 33 1.38 [1.06, 1.79] 
Tang JL 2011, Han SK 2011 25 40 23 40 1.09 [0.76, 1.56] 
Xu YJ 2015 34 36 13 26 1.89 [1.28, 2.80]  
Effective rate of improvement in stool consistency 
Li QJ 2015 32 34 20 28 1.32 [1.03, 1.69] 
Tang JL 2011, Han SK 2011 26 40 17 40 1.53 [1.00, 2.34] 
Xu YJ 2015 33 37 13 36 2.47 [1.58, 3.87]  
Effective rate of diarrhea (not distinguishing between frequency or consistency) 
Wang HL 2006 28 30 27 30 1.04 [0.89, 1.21] 
Yu C 2013 29 30 18 30 1.61 [1.19, 2.17] 
Yu SL 2007 34 39 25 37 1.29 [1.00, 1.66] 
Zhang SS 2004 32 36 33 36 0.97 [0.83, 1.13] 
Table 6 
Summary of findings table.        
Outcomes Anticipated absolute effects* (95% CI) Relative effect (95 % 
CI) 
№ of participants 
(studies) 
Certainty of the evidence 
(GRADE) 
Risk with 
Probiotics 
Risk with CHM  
Overall symptomsimproving rate 719 per 1000 892 per 1000 
(849–935) 
RR 1.24 (1.18–1.30) 3207 (41 RCTs) ⨁○○○ VERY LOW a,b,d 
Relapse rate 437 per 1000 118 per 1000 (79–175) RR 0.27 (0.18 –0.40) 382 (5 RCTs) ⨁○○○ VERY LOW a,c 
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: 
We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low 
certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Explanations. 
a Downgraded by two levels: inadequate concealment of allocation, unblinded participants and personnel, and unblinded assessment of outcome. 
b Downgraded by one level: asymmetric funnel plot. 
c Downgraded by one level: total number of events is less than 300. 
d Downgraded by one level: I2 > 50 %. 
* The risk in the intervention group (and its 95 % confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95 % CI). CI: Confidence interval; RR: Risk ratio.  
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shown that CHM may be superior to probiotics in improving specific 
symptoms to varying degrees, due to insufficient data, certainty of 
evidence is not yet available. Also, due to limited data, the efficacy of 
CHM versus probiotics on IBS-C and IBS-M is not yet apparent. 
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